Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/59019
Full metadata record
DC FieldValueLanguage
dc.contributor.authorÖzdemir, M.-
dc.contributor.authorGököz Doğu, G.-
dc.contributor.authorYapar Taşköylü, B.-
dc.contributor.authorDemiray, A.G.-
dc.contributor.authorDeğirmencioğlu, S.-
dc.contributor.authorYaren, A.-
dc.contributor.authorArslan, Muhammet-
dc.contributor.authorÇakan Demirel, Burçin-
dc.contributor.authorDoğan, Tolga-
dc.contributor.authorGüçlü Kantar, Taliha-
dc.contributor.authorTaş, Semra-
dc.contributor.authorAçıkgöz Yıldız, Bedriye-
dc.contributor.authorSerin Özel, Gamze-
dc.contributor.authorMordağ Çiçek, Ceren-
dc.date.accessioned2025-02-20T19:16:13Z-
dc.date.available2025-02-20T19:16:13Z-
dc.date.issued2025-
dc.identifier.issn1309-9833-
dc.identifier.urihttps://doi.org/10.31362/patd.1471860-
dc.identifier.urihttps://hdl.handle.net/11499/59019-
dc.description.abstractPurpose: We examined the relationship between albumin and C reactive protein (CRP)-related inflammation markers such as Controlling nutritional status (Conut) score, lymphocyte-albumin factor (LA), albumin-bilirubin score (ALBI), highly sensitive modified Glasgow prognostic score (Hs-mGPS), Glasgow prognostic score (GPS) and locoregional treatment response in HCC. Materials and methods: One hundred and eighty HCC patients and 63 patients who underwent locoregional therapy were included in this study. Routine laboratory tests between the fourth and eighth week after treatment were recorded and albumin and CRP-related immuno-nutrition scores were calculated. Cut-off values from the literature were used. The predictive and prognostic value of these markers for overall survival (OS) and disease-free survival (DFS) after treatment were analyzed. Results: The mean age was 63 years (min-max:26-87) and 59 (93.7%) of the patients were male. The mean follow-up period was 25 months and 53 patients were deceased (84.1%). Median overall survival (mOS):18.56 months (min-max:13.13-23.99); median disease-free survival (mDFS):7 months (min-max:3.63-10.37) after locoregional treatment. Age (p=0.019), Conut (p=0.001), GPS (p=0.028), Hs-mGPS (p=0.012), LA (p=0.017) and ALBI (p=0.002) were significantly correlated with mOS. Conut (p=0.002), GPS (p<0.001), Hs-mGPS (p=0.002), LA (p=0.002) and ALBI (p=0.001) were significantly correlated with mDFS. Multivariate analysis revealed that those aged ≥65 years (HR:2.10; 95% CI:1.02-4.30; p=0.042) and those who received no systemic therapy (HR:4.11; 95% CI:1.35-12.56; p=0.013) had an increased risk of death (p<0.001). Another significant result was that a GPS of '2' (HR:6.62; 95% CI:1.13-38.62; p=0.036) predicted a higher risk of progression (p<0.001). Conclusion: In this study, we found that age, Conut score, GPS, HsmGPS, LA and ALBI score significantly predicted mOS and mDFS in locoregionally treated HCC patients. All these results suggest that our prognostic modelling may be useful in clinical practice. © 2025, Pamukkale University. All rights reserved.en_US
dc.language.isoenen_US
dc.publisherPamukkale Universityen_US
dc.relation.ispartofPamukkale Medical Journalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConut Scoreen_US
dc.subjectGpsen_US
dc.subjectHccen_US
dc.subjectHsmgpsen_US
dc.subjectTaceen_US
dc.titleUse of albumin and CRP related i̇mmuno-nutritional markers for prediction of locoregional response to treatment i̇n unresectable hepatocellular carcinomaen_US
dc.title.alternativeİnoperable Hepatosellüler karsinom’da lokorejyonel tedavi yanıtını öngörmek için albümin ve CRP ilişkili immüno-nutrisyon belirteçlerin kullanımıen_US
dc.typeArticleen_US
dc.identifier.volume18en_US
dc.identifier.issue1en_US
dc.identifier.startpage87en_US
dc.identifier.endpage97en_US
dc.departmentPamukkale Universityen_US
dc.identifier.doi10.31362/patd.1471860-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57197179294-
dc.authorscopusid9534426600-
dc.authorscopusid36961379700-
dc.authorscopusid57200169071-
dc.authorscopusid22333756200-
dc.authorscopusid12759416700-
dc.authorscopusid59505927600-
dc.identifier.scopus2-s2.0-85214484726-
dc.identifier.scopusqualityQ4-
dc.identifier.wosqualityN/A-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.fulltextWith Fulltext-
item.openairetypeArticle-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
Show simple item record



CORE Recommender

Page view(s)

24
checked on May 11, 2025

Download(s)

6
checked on May 11, 2025

Google ScholarTM

Check





Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.